Typic and Atypic Antipsychotic Drugs: Comparison of Their Effects on Blood Sugar in Schizophrenic Patients

Document Type : Research Paper

Authors

1 Associated Professor of Endocrinology, Mashhad University of Medical Sciences, Mashhad,

2 Associated Professor of psychiatry, Mashhad University of Medical Sciences, Mashhad,

3 Psychiatry specialist,Tehran,

4 Assistant Professor of Endocrinology, Mashhad University of Medical Sciences, Mashhad,

Abstract

Introduction
Antipsychotic drugs are the cornerstone of schizophrenia treatment. Glucoregulatory abnormalities have been associated with the use of antipsychotic medications. There are some reports of weight gain and glucose intolerance in patients with schizophrenia receiving atypical antipsychotic medications. The purpose of this study is to compare the effect of various antipsychotic therapies on glycemic control in patients with schizophrenia.
Materials and Methods
Eighty-one patients with schizophrenia were enrolled in the study and underwent glucose-tolerance test. Patients were divided in to two groups, with one group (n=43) receiving typical and the other group (n=38) receiving atypical medication. Demographical and historical data were collected with a questionnaire.
Results
There was a marginally significant difference in the first hour glucose level between typical and atypical drugs (mean 132.12 vs. 151.76, respectively, p=0.07). Also, marginal significant difference was present comparing the first hour glucose level between typical antipsychotics and clozapine consumers (mean 132.12 vs. 153.67, p=0.06). This difference was not present when typical antipsychotics were compared with risperidone (mean 132.12 vs. 149.41, p=0.230). Fasting blood sugar and second- hour glucose tolerance results did not show a statistically significant difference. The increased GTT of the first hour blood sugar in patients who received clozapin may indicate the early stages of insulin resistance in this group.
Conclusion
This study suggests that patients under atypical antipsychotic treatment are more vulnerable to diabetes mellitus (DM). Across atypical medications; we observed a greater glycemic effect from clozapin compared to risperidone.

Keywords

References

1. Rethelyi J, Sawalhe AD. [Comorbidity of metabolic syndrome, diabetes and schizophrenia: theoretical and practical
considerations]. Orv Hetil 2011; 152:505-511.
2. Baptista T, Serrano A, Uzcategui E, ElFakih Y, Rangel N, Carrizo E, et al. Themetabolic syndrome and its
constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free
psychiatric patients, first-degree relatives and the general population in Venezuela. Schizophr Res 2011; 2:102-193.
3. Sato Y, Yasui-Furukori N, Kaneko S, Moriyama T. New-onset diabetic ketoacidosis in a schizophrenic patient with
multiple autoimmune disease during treatment with risperidone. Prog Neuropsychopharmacol Biol Psychiatry 2008;
32:5.
4. Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose
tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic
medications. J Clin Psychiatry 1998; 59:294-299.
5. Sato Y, Yasui-Furukori N, Furukori H, Saito M, Nakagami T, Kaneko S. A crossover study on the glucose
metabolism between treatment with olanzapine and risperidone in schizophrenic patients. Exp Clin Psychopharmacol
2010; 8:445-450.
6.Kessing LV, Thomsen AF, Mogensen UB, Andersen PK. Treatment with antipsychotics and the risk of diabetes in
clinical practice. Br J Psychiatry 2010; 197:266-271.
7. Philippe A, Vaiva G, Casadebaig F. Data on diabetes from the Frenchcohort study in schizophrenia. Eur Psychiatry
2005; 4:S340-3444.
8. Smith RC, Lindenmayer JP, Davis JM, Kelly E, Viviano TF, Cornwell J, et al. Effects of olanzapine and risperidone
on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment:
a randomized 5-month study. J Clin Psychiatry 2009; 70:1501-1513.
9.Lamberti JS, Costea GO, Olson D, Crilly JF, Maharaj K, Tu X, et al. Diabetes mellitus among outpatients receiving
clozapine: prevalence and clinical-demographic correlates. J Clin Psychiatry 2005; 66:900-606.
10. Pringsheim T, Panagiotopoulos C, Davidson J, Ho J. Evidence-based recommendations for monitoring safety of
second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry 2011; 20:218-233.
Medical Journal of Mashhad university of Medical Sciences
Volume 55, Issue 3 - Serial Number 3
March and April 2012
Pages 139-143

Files

Share

How to cite

Statistics